Skip to main content


Fig. 4 | Clinical and Translational Allergy

Fig. 4

From: Evidence of the efficacy and safety of house dust mite subcutaneous immunotherapy in elderly allergic rhinitis patients: a randomized, double-blind placebo-controlled trial

Fig. 4

Increase in HDM-specific IgG4 levels (SE) after 12 and 24 months following the start of treatment. D. pter_—the mean change of IgG4 against D. pteronyssinus from baseline, D. far—mean change of IgG4 against D. farinae from baseline, Derp1—the mean change of IgG 4 against antigen D pter 1 from baseline, Derp2—the mean change of IgG4 against antigen D pter 2 from baseline

Back to article page